Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656965 | 0.84 | GAA (0.59) | MAPTSMN1; SMN2 | |
| SCHEMBL6661623 | 0.82 | L3MBTL1 (0.51) | — | |
| SCHEMBL3267566 | 0.82 | BRD4 (0.54) | FAAHBRD4CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL6937314 | 0.82 | MEN1 (0.62) | FAAHBRD4CYSLTR2CYSLTR1LTA4H | |
| Hydrochloric Acid SCHEMBL31742267 | 0.81 | BRD4 (0.53) | FAAHBRD4CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL8981963 | 0.80 | BRD4 (0.56) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL3466988 | 0.80 | CYSLTR2 (0.59) | FAAHBRD4CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL6328916 | 0.79 | MAPT (0.55) | FAAHBRD4CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL12549253 | 0.79 | LTA4H (0.59) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL3257350 | 0.79 | BRD4 (0.54) | FAAHBRD4CYSLTR2CYSLTR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825354-B2 | OSTEOPOROSIS; RHEUMATIC DISEASES | WYETH HOLDINGS CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | FAAH 560/4885BRD4 2790/4885CYSLTR2 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.